GlassScriptPhysician profile
Charlotte A Birnbaum
NPI 1649680737
$5,548.95
in general payments reported to CMS, 2019-2025
26 companies · $759 in 2025
The $759 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $452 · 2021: $825 · 2022: $1,116 · 2023: $756 · 2024: $379 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.24 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $847.91 | 2019-2025 | |
| Janssen Biotech, INC. | $787.38 | 2020-2025 | Tremfya |
| Abbvie INC. | $768.37 | 2020-2025 | Skyrizi, Botox |
| Incyte Corporation | $546.95 | 2021-2025 | Opzelura, Opzelura |
| Allergan, INC. | $507.24 | 2019 | |
| Genzyme Corporation | $268.27 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $267.71 | 2021-2025 | Cabtreo, Jublia |
| Regeneron Healthcare Solutions, INC. | $206.25 | 2021-2025 | Dupixent |
| Almirall LLC | $196.22 | 2019-2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $142.02 | 2020-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $123.64 | 2020-2023 | Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $119.99 | 2019-2023 | |
| Epi Health, LLC | $112.01 | 2020-2022 | |
| Dermavant Sciences, INC. | $105.77 | 2023-2024 | Vtama |
| Journey Medical Corporation | $94.77 | 2020-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $89.19 | 2020-2021 | |
| Amgen INC. | $75.91 | 2022-2025 | Otezla |
| Pfizer INC. | $74.22 | 2021-2023 | |
| Leo Pharma INC. | $63.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.30 | 2024-2025 | |
| Ucb, INC. | $23.79 | 2022 | |
| Celgene Corporation | $17.38 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.99 | 2019 | |
| Botanix Sb INC | $15.93 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $15.19 | 2024 | Xtrac |
| Merz North America, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.